VRTX Stock Summary and Trading Ideas (Vertex Pharmaceuticals | NASDAQ:VRTX)

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Vertex Pharmaceuticals trades on the NASDAQ stock market under the symbol VRTX.

As of October 6, 2026, VRTX stock price declined to $502.31 with 689,272 million shares trading.

VRTX has a beta of 0.43, meaning it tends to be less sensitive to market movements. VRTX has a correlation of 0.04 to the broad based SPY ETF.

VRTX has a market cap of $127.32 billion. This is considered a Large Cap stock.

Last quarter Vertex Pharmaceuticals reported $3 billion in Revenue and $4.73 earnings per share. This beat revenue expectation by $120 million and exceeded earnings estimates by $.10.

In the last 3 years, VRTX traded as high as $560.25 and as low as $341.90.

The top ETF exchange traded funds that VRTX belongs to (by Net Assets): VTI, VOO, QQQ, IVV, SPY.

VRTX has outperformed the market in the last year with a return of +24.5%, while the SPY ETF gained +17.6%. However, in the most recent history, VRTX shares have underperformed the stock market with its stock returning -4.9% in the last 3 month period and -1.6% for the last 2 week period, while SPY has returned +4.9% and +0.7%, respectively.

VRTX support price is $495.09 and resistance is $511.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRTX shares will trade within this expected range on the day.